Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1085827

Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment


(ESC Working Group on Thrombosis Young Researchers) Gasecka, Aleksandra; Borovac, Josip Anđelo; Azevedo Guerreiro, Rui; Giustozzi, Michela; Parker, William; Caldeira, Daniel; Chiva- Blanch, Gemma
Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment // Cardiovascular drugs and therapy (2020) doi:10.1007/s10557-020-07084-9 (znanstveni, prihvaćen)


CROSBI ID: 1085827 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment

Autori
Gasecka, Aleksandra ; Borovac, Josip Anđelo ; Azevedo Guerreiro, Rui ; Giustozzi, Michela ; Parker, William ; Caldeira, Daniel ; Chiva- Blanch, Gemma

Kolaboracija
ESC Working Group on Thrombosis Young Researchers

Vrsta, podvrsta
Radovi u časopisima, znanstveni

Izvornik
Cardiovascular drugs and therapy (2020)

Status rada
Prihvaćen

Ključne riječi
COVID-19 ; SARS-CoV-2 ; Thrombosis ; Inflammation ; Venous thromboembolism ; Prophylaxis ; Treatment ; Heaemostasis

Sažetak
Introduction: Emerging evidence points to an association between severe clinical presentation of COVID- 19 and increased risk of thromboembolism. One- third of patients hospitalized due to severe COVID-19 develops macrovascular thrombotic complications, including venous thromboembolism, myocardial injury/infarction and stroke. Concurrently, the autopsy series indicate multiorgan damage pattern consistent with microvascular injury. Prophylaxis, diagnosis and treatment: COVID-19 associated coagulopathy has distinct features, including markedly elevated D-dimers concentration with nearly normal activated partial thromboplastin time, prothrombin time and platelet count. The diagnosis may be challenging due to overlapping features between pulmonary embolism and severe COVID-19 disease, such as dyspnoea, high concentration of D- dimers, right ventricle with dysfunction or enlargement, and acute respiratory distress syndrome. Both macro- and microvascular complications are associated with an increased risk of in-hospital mortality. Therefore, early recognition of coagulation abnormalities among hospitalized COVID-19 patients are critical measures to identify patients with poor prognosis, guide antithrombotic prophylaxis or treatment, and improve patients’ clinical outcomes. Recommendations for clinicians: Most of the guidelines and consensus documents published on behalf of professional societies focused on thrombosis and hemostasis advocate the use of anticoagulants in all patients hospitalized with COVID-19, as well as 2-6 weeks post hospital discharge in the absence of contraindications. However, since there is no guidance for deciding the intensity and duration of anticoagulation, the decision- making process should be made in individual- case basis. Conclusions: Here, we review the mechanistic relationships between inflammation and thrombosis, discuss the macrovascular and microvascular complications and summarize the prophylaxis, diagnosis and treatment of thromboembolism in patients affected by COVID- 19.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

Napomena
Aleksandra Gąsecka and Josip A. Borovac share
joint first authorship—these authors contributed
equally to this work.



POVEZANOST RADA


Ustanove
Medicinski fakultet, Split

Profili:

Avatar Url JOSIP ANĐELO BOROVAC (autor)

Citiraj ovu publikaciju

(ESC Working Group on Thrombosis Young Researchers) Gasecka, Aleksandra; Borovac, Josip Anđelo; Azevedo Guerreiro, Rui; Giustozzi, Michela; Parker, William; Caldeira, Daniel; Chiva- Blanch, Gemma
Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment // Cardiovascular drugs and therapy (2020) doi:10.1007/s10557-020-07084-9 (znanstveni, prihvaćen)
(ESC Working Group on Thrombosis Young Researchers) (ESC Working Group on Thrombosis Young Researchers) Gasecka, A., Borovac, J., Azevedo Guerreiro, R., Giustozzi, M., Parker, W., Caldeira, D. & Chiva- Blanch, G. (2020) Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment. Prihvaćen za objavljivanje u Cardiovascular drugs and therapy. [Preprint] doi:10.1007/s10557-020-07084-9.
@unknown{unknown, year = {2020}, DOI = {10.1007/s10557-020-07084-9}, keywords = {COVID-19, SARS-CoV-2, Thrombosis, Inflammation, Venous thromboembolism, Prophylaxis, Treatment, Heaemostasis}, journal = {Cardiovascular drugs and therapy}, doi = {10.1007/s10557-020-07084-9}, title = {Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment}, keyword = {COVID-19, SARS-CoV-2, Thrombosis, Inflammation, Venous thromboembolism, Prophylaxis, Treatment, Heaemostasis} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font